Table 5 Common adverse events (n=28)

From: Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

 

No. of patients (%)

Adverse events

Grade 1

Grade 2

Grade 3

Grade 4

Haematologic

 Anaemia

12 (43)

3 (11)

0 (0)

0 (0)

 Leucopaenia

4 (14)

1 (4)

2 (7)

0 (0)

 Neutropaenia

4 (14)

1 (4)

1 (4)

0 (0)

 Thrombocytopaenia

3 (11)

0 (0)

0 (0)

0 (0)

Nonhaematologic

 Rash

10 (36)

11 (39)

2 (7)

0 (0)

 Dry skin

9 (32)

10 (36)

0 (0)

0 (0)

 Nail changes

5 (18)

2 (7)

0 (0)

0 (0)

 Keratitis

0 (0)

0 (0)

1 (4)

0 (0)

 Fever

0 (0)

1 (4)

0 (0)

0 (0)

 Fatigue

3 (10)

3 (10)

3 (10)

0 (0)

 Diarrhoea

7 (25)

1 (4)

0 (0)

0 (0)

 Constipation

1 (4)

0 (0)

0 (0)

0 (0)

 Stomatitis

8 (29)

1 (4)

0 (0)

0 (0)

 Gastritis

1 (4)

0 (0)

0 (0)

0 (0)

 Anorexia

2 (7)

1 (4)

0 (0)

0 (0)

 Nausea

3 (11)

1 (4)

0 (0)

0 (0)

 Vomiting

2 (7)

2 (7)

1 (4)

0 (0)

 Dyspnoea

2 (7)

0 (0)

1 (4)

0 (0)

 ILD

2 (7)

0 (0)

0 (0)

1 (4)a

 Vertigo

1 (4)

1 (4)

0 (0)

0 (0)

 Dysgeusia

0 (1)

1 (4)

0 (0)

0 (0)

 Elevated AST/ALT

10 (36)

2 (7)

4 (14)

1 (4)a

 Elevated creatinine

2 (7)

1 (4)

2 (7)

0 (0)

  1. ALT=alanine transaminase; AST=aspartate transaminase; ILD=interstitial lung disease.
  2. aSame patient.
Back to article page